Efficacy and Safety of Lidocaine Ointment for Cancer Skin-Related Pain

Efficacy and Safety of Lidocaine Ointment for Cancer Skin-Related Pain - Lidocaine Ointment for Cancer Skin-Related Pain

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000056391

Enrollment

Registered

2025-03-01

Start date

2025-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer skin-related pain

Interventions

Application of 2% lidocaine ointment Application of placebo ointment

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histopathological or clinical diagnosis of solid cancer. 2) Patient has cancer pain due to cancer skin-related pain (e.g., cancer skin infiltration pain). (3) Worst pain intensity NRS of cancer skin-related pain in the last 24 hours is 4 or more.

Exclusion criteria

Exclusion criteria: 1) Patients with drug allergy to amide-type local anesthetics. (2) Patients whose regularly administered analgesic agent has been changed within 24 hours prior to enrollment. 3) Patients who are receiving radiotherapy for tumors with cancer skin-related pain.

Design outcomes

Primary

Measure	Time frame
Percentage of patients with at least 50% improvement in worst pain intensity NRS in the last 24 hours after the first 72 hours of application	—

Countries

Japan

Contacts

Public ContactHideaki Hasuo

Kansai Medical University Department of Psychosomatic Medicine

hasuohid@hirakata.kmu.ac.jp0728040101

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026